<DOC>
	<DOC>NCT01173939</DOC>
	<brief_summary>The study is being conducted to compare the effect of standard treatment (target LDL-C level: &lt;120 mg/dL (JASGL 2007 target level)) and intensive treatment (target LDL-C level: &lt;70 mg/dL) in the prevention of major adverse cardiac events (MACE) in hypercholesterolemia patients with concomitant type 2 diabetes and hypertension.</brief_summary>
	<brief_title>Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event Assessments</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Patients meeting the following inclusion criteria will be included in the study: 1. Patients giving voluntary written consent to participate in the study 2. Male or female patients 50 years of age or older (at informed consent) 3. Hypercholesterolemia patients (Untreated patients: LDLC level ≥140 mg/dL; treated patients: LDLC level ≥120 mg/dL) 4. Type 2 diabetes patients (HbA1c level ≥6.1% (JDS criteria), with or without history of drug therapy) 5. Hypertension patients (SBP ≥130 mmHg or DBP ≥80 mmHg, with or without history of drug therapy) 6. Patients with two or more of the following risk factors Male 65 years of age or older Smoker L/H ratio: ≥3.0 •HbA1c level: ≥8.0% Left ventricular hypertrophy First or seconddegree family history of MACE Microalbuminuria (quantitative testing: ≥30 mg/dL), proteinuria (qualitative testing: + or higher) or eGFR (&lt;60 mL/min/1.73 m2) Patients meeting the following criteria will be excluded from the study: 1. Patients receiving rosuvastatin, pitavastatin, or atorvastatin therapy within one month prior to informed consent 2. Patients judged to have familial hypercholesterolemia 3. Patients with a serum triglyceride level of ≥400 mg/dL 4. Patients with a history of myocardial infarction 5. Patients with a history of coronary revascularization (PCI or CABG) 6. Patients with a history of treatment of unstable angina 7. Patients with a history of cerebrovascular accident (excluding asymptomatic lacunar infarction) 8. Heart failure patients 9. Patients with a history of hypersensitivity to statins 10. Patients with a history of druginduced myopathy 11. Patients with poorly controlled arrhythmia 12. Patients with severe liver or kidney disease 13. Patients with serious concurrent disease, such as malignancy, or patients with severely limited lifespan 14. Patients who are or may be pregnant 15. Patients judged by the investigators to be ineligible for participation in the study for any other reason</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Hypercholesterolemia with concomitant type 2 diabetes and hypertension</keyword>
</DOC>